Market Tracker

01/20 5:16pm ET

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

38.96
Delayed Data
As of 4:00pm ET
 -0.12 / -0.31%
Today’s Change
31.38
Today|||52-Week Range
80.19
+4.06%
Year-to-Date
The Medicines Co LDL-Lowering Drug Positive in Phase II
Jan 09 / Zacks.com - Paid Partner Content
Here's Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
Jan 07 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close39.08
Today’s open39.12
Day’s range38.02 - 39.22
Volume817,805
Average volume (3 months)1,537,673
Market cap$3.4B
Dividend yield--
Data as of 4:00pm ET, 01/20/2017

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-40.53%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book2.63

Competitors

 Today’s
change
Today’s
% change
CTLTCatalent Inc+0.25+0.96%
GLPGGalapagos NV+0.01+0.02%
GWPHGW Pharmaceuticals P...+1.36+1.15%
CBPOChina Biologic Produ...+0.43+0.40%
Data as of 4:02pm ET, 01/20/2017

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)-$1.32
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts